nxp900
nxp900: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Nuvectis Pharma, Inc. (NVCT) | Phase 1 |
Clinical Trials (1)
A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer
Frequently asked questions
Who is developing nxp900?
nxp900 is being developed by Nuvectis Pharma, Inc..
How many clinical trials involve nxp900?
BioSniper tracks 1 clinical trial involving nxp900.
Get deeper analysis on nxp900
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis